<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01737944</url>
  </required_header>
  <id_info>
    <org_study_id>MTX-10-001</org_study_id>
    <nct_id>NCT01737944</nct_id>
  </id_info>
  <brief_title>Exposure Study Comparing 3 Routes of Methotrexate (MTX) Administration</brief_title>
  <official_title>Exposure, Safety and Local Tolerance Study Comparing 3 Routes of Methotrexate (MTX) Administration: Vibex-MTX Device, Subcutaneous (SC)and Intramuscular (IM) in Adult Subjects With Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Antares Pharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Antares Pharma Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pharmacokinetics (PK) study
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare the pharmacokinetic (PK) profiles of methotrexate (MTX) following a subcutaneous
      (SC) injection of MTX using the Vibex device to that obtained after an SC injection of MTX
      without using the device and to that obtained after an intramuscular (IM) injection of MTX in
      adult subjects with rheumatoid arthritis (RA).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence Based Upon Dose-Normalized AUC[0-Inf] for MTX</measure>
    <time_frame>24 Hour period</time_frame>
    <description>Dose-normalized area under the curve from time zero to infinity (AUC[0-inf]/Dose) for each treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bioequivalence Based Upon Dose-Normalized AUC[0-24] for MTX</measure>
    <time_frame>24 Hour period</time_frame>
    <description>Dose-normalized area under the curve from time zero to 24 hours post-dose (AUC[0-24]/Dose) for each treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bioequivalence Based Upon Dose-Normalized Cmax for MTX</measure>
    <time_frame>24 Hour period</time_frame>
    <description>Dose-normalized maximum observed concentration for each treatment</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>10mg Methotrexate (MTX) Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Arm A - SC injection with Vibex device, Treatment Arm B - SC injection without device and Treatment Arm C - IM injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>15mg Methotrexate (MTX) Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Arm A - SC injection with Vibex device, Treatment Arm B - SC injection without device and Treatment Arm C - IM injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20mg Methotrexate (MTX) Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Arm A - SC injection with Vibex device, Treatment Arm B - SC injection without device and Treatment Arm C - IM injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>25mg Methotrexate (MTX) Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Arm A - SC injection with Vibex device, Treatment Arm B - SC injection without device and Treatment Arm C - IM injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate (MTX)</intervention_name>
    <description>Vibex MTX Device</description>
    <arm_group_label>10mg Methotrexate (MTX) Group</arm_group_label>
    <arm_group_label>15mg Methotrexate (MTX) Group</arm_group_label>
    <arm_group_label>20mg Methotrexate (MTX) Group</arm_group_label>
    <arm_group_label>25mg Methotrexate (MTX) Group</arm_group_label>
    <other_name>Device with MTX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female &gt;18 years of age with diagnosed Rheumatoid Arthritis(RA).

        Exclusion Criteria:

          -  Chronic or acute renal disease

          -  Any other clinically significant disease or disorder which, in the opinion of the
             investigator, might put the subject at risk
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan J Kivitz, MD;CPI</last_name>
    <role>Principal Investigator</role>
    <affiliation>Altoona Center for Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Altoona Center for Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 27, 2012</study_first_submitted>
  <study_first_submitted_qc>November 28, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2012</study_first_posted>
  <results_first_submitted>January 25, 2013</results_first_submitted>
  <results_first_submitted_qc>January 8, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 25, 2014</results_first_posted>
  <last_update_submitted>January 8, 2014</last_update_submitted>
  <last_update_submitted_qc>January 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>methotrexate injection, subcutaneous, autoinjector</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were screened and enrolled at 2 sites in the US. Approximately equal number of subjects on 10 mg, 15 mg, 20 mg and 25 mg doses were recruited. The dose group was determined by the Investigator based on subject's current therapeutic regimen of MTX and disease status. The patient's dose was the same for the entire study.</recruitment_details>
      <pre_assignment_details>The order of Methotrexate (MTX) treatment arms (A-SC injection with Vibex-MTX device, B-SC injection without device and C-IM Injection) were randomly assigned and dosing was separated by interval of atleast 7 days to allow for washout before the next treatment was administered.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>10mg MTX Group</title>
          <description>[administered via randomized sequence and crossover of Treatment Arm A -SC injection with Vibex MTX device, Treatment Arm B -SC injection without device and Treatment Arm C -IM Injection]</description>
        </group>
        <group group_id="P2">
          <title>15mg MTX Group</title>
          <description>[administered via randomized sequence and crossover of Treatment Arm A -SC injection with Vibex MTX device, Treatment Arm B -SC injection without device and Treatment Arm C -IM Injection]</description>
        </group>
        <group group_id="P3">
          <title>20mg MTX Group</title>
          <description>[administered via randomized sequence and crossover of Treatment Arm A -SC injection with Vibex MTX device, Treatment Arm B -SC injection without device and Treatment Arm C -IM Injection]</description>
        </group>
        <group group_id="P4">
          <title>25mg MTX Group</title>
          <description>[administered via randomized sequence and crossover of Treatment Arm A -SC injection with Vibex MTX device, Treatment Arm B -SC injection without device and Treatment Arm C -IM Injection]</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9">10 patients randomized, one patient discontinued before first study drug dose</participants>
                <participants group_id="P4" count="9">10 patients randomized, one patient discontinued before first study drug dose</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>38 subjects were randomized to a treatment sequence. Two subjects discontinued prior to receiving the first study drug dose. Safety Population = 36 subjects who received study drug and completed all study visits. All 36 subjects were included in Pharmacokinetic Population. No discontinuations after first study drug dose.</population>
      <group_list>
        <group group_id="B1">
          <title>10mg MTX Group</title>
          <description>[Administered via randomized sequence and crossover of Treatment Arm A, Treatment Arm B and Treatment Arm C]</description>
        </group>
        <group group_id="B2">
          <title>15mg MTX Group</title>
          <description>[Administered via randomized sequence and crossover of Treatment Arm A, Treatment Arm B and Treatment Arm C]</description>
        </group>
        <group group_id="B3">
          <title>20mg MTX Group</title>
          <description>[Administered via randomized sequence and crossover of Treatment Arm A, Treatment Arm B and Treatment Arm C]</description>
        </group>
        <group group_id="B4">
          <title>25mg MTX Group</title>
          <description>[Administered via randomized sequence and crossover of Treatment Arm A, Treatment Arm B and Treatment Arm C]</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="9"/>
            <count group_id="B5" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.2" spread="10.97"/>
                    <measurement group_id="B2" value="63.4" spread="7.26"/>
                    <measurement group_id="B3" value="60.8" spread="6.18"/>
                    <measurement group_id="B4" value="63.0" spread="6.80"/>
                    <measurement group_id="B5" value="62.1" spread="7.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Bioequivalence Based Upon Dose-Normalized AUC[0-Inf] for MTX</title>
        <description>Dose-normalized area under the curve from time zero to infinity (AUC[0-inf]/Dose) for each treatment</description>
        <time_frame>24 Hour period</time_frame>
        <population>The Population was defined as all randomized subjects who received at least 1 dose of study drug and who had at least 1 valid post-dose plasma concentration value.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>Subcutaneous (SC) injection with the Vibex MTX device</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>SC injection of MTX without the device</description>
          </group>
          <group group_id="O3">
            <title>Treatment Arm C</title>
            <description>Intramuscular (IM) injection of MTX</description>
          </group>
        </group_list>
        <measure>
          <title>Bioequivalence Based Upon Dose-Normalized AUC[0-Inf] for MTX</title>
          <description>Dose-normalized area under the curve from time zero to infinity (AUC[0-inf]/Dose) for each treatment</description>
          <population>The Population was defined as all randomized subjects who received at least 1 dose of study drug and who had at least 1 valid post-dose plasma concentration value.</population>
          <units>ng*hr/mL/mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.14" spread="42.300" lower_limit="55.65" upper_limit="213.94"/>
                    <measurement group_id="O2" value="122.63" spread="40.648" lower_limit="80" upper_limit="125"/>
                    <measurement group_id="O3" value="116.71" spread="41.394" lower_limit="80" upper_limit="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The bioequivalence of Methotrexate following Treatment A - SC injection with the Vibex MTX device and Treatment B - SC injection without the device was established if the 90% CI for the geometric LS Mean ratios of AUC(0-inf)/Dose were within the range of 80% to 125%.</non_inferiority_desc>
            <param_type>Test / Reference Ratio</param_type>
            <param_value>96.24</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>92.33</ci_lower_limit>
            <ci_upper_limit>100.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The bioequivalence of Methotrexate following Treatment A-SC injection with the Vibex MTX device and Treatment C-IM injection was established if the 90% CI for the geometric LS Mean ratios of AUC(0-inf)/Dose were within the range of 80% to 125%.</non_inferiority_desc>
            <param_type>Test / Reference Ratio</param_type>
            <param_value>101.28</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>97.17</ci_lower_limit>
            <ci_upper_limit>105.56</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Bioequivalence Based Upon Dose-Normalized AUC[0-24] for MTX</title>
        <description>Dose-normalized area under the curve from time zero to 24 hours post-dose (AUC[0-24]/Dose) for each treatment</description>
        <time_frame>24 Hour period</time_frame>
        <population>Dose-normalized MTX PK parameter AUC(0-24)/Dose used for comparison</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>Subcutaneous (SC) injection with the Vibex MTX device</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>SC injection of MTX without the device</description>
          </group>
          <group group_id="O3">
            <title>Treatment Arm C</title>
            <description>Intramuscular (IM) injection of MTX</description>
          </group>
        </group_list>
        <measure>
          <title>Bioequivalence Based Upon Dose-Normalized AUC[0-24] for MTX</title>
          <description>Dose-normalized area under the curve from time zero to 24 hours post-dose (AUC[0-24]/Dose) for each treatment</description>
          <population>Dose-normalized MTX PK parameter AUC(0-24)/Dose used for comparison</population>
          <units>ng*hr/mL/mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.60" spread="40.963"/>
                    <measurement group_id="O2" value="121.08" spread="39.405"/>
                    <measurement group_id="O3" value="122.63" spread="40.648"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The bioequivalence of Methotrexate following Treatment A-SC injection with the Vibex MTX device and Treatment B-SC injection was established if the 90% CI for the geometric LS Mean ratios of AUC(0-24)/Dose were within the range of 80% to 125%.</non_inferiority_desc>
            <param_type>Test / Reference Ratio</param_type>
            <param_value>96.22</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>92.32</ci_lower_limit>
            <ci_upper_limit>100.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The bioequivalence of Methotrexate following Treatment A-SC injection with the Vibex MTX device and Treatment C-IM injection was established if the 90% CI for the geometric LS Mean ratios of AUC(0-24)/Dose were within the range of 80% to 125%.</non_inferiority_desc>
            <param_type>Test / Reference Ratio</param_type>
            <param_value>101.14</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>97.06</ci_lower_limit>
            <ci_upper_limit>105.40</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Bioequivalence Based Upon Dose-Normalized Cmax for MTX</title>
        <description>Dose-normalized maximum observed concentration for each treatment</description>
        <time_frame>24 Hour period</time_frame>
        <population>The Population was defined as all randomized subjects who received at least 1 dose of study drug and who had at least 1 valid post-dose plasma concentration value.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>Subcutaneous (SC) injection with the Vibex MTX device</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>SC injection of MTX without the device</description>
          </group>
          <group group_id="O3">
            <title>Treatment Arm C</title>
            <description>Intramuscular (IM) injection of MTX</description>
          </group>
        </group_list>
        <measure>
          <title>Bioequivalence Based Upon Dose-Normalized Cmax for MTX</title>
          <description>Dose-normalized maximum observed concentration for each treatment</description>
          <population>The Population was defined as all randomized subjects who received at least 1 dose of study drug and who had at least 1 valid post-dose plasma concentration value.</population>
          <units>ng/mL/mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.43" spread="8.310"/>
                    <measurement group_id="O2" value="22.38" spread="10.263"/>
                    <measurement group_id="O3" value="23.37" spread="7.188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The bioequivalence of Methotrexate following Treatment A-SC injection with the Vibex MTX device and Treatment B-SC injection without the device was established if the 90% CI for the geometric LS Mean ratios of Cmax/Dose were within the range of 80% to 125%.</non_inferiority_desc>
            <param_type>Test / Reference Ratio</param_type>
            <param_value>96.76</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>87.93</ci_lower_limit>
            <ci_upper_limit>106.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The bioequivalence of Methotrexate following Treatment A-SC injection with the Vibex MTX device and Treatment C-IM injection was established if the 90% CI for the geometric LS Mean ratios of Cmax/Dose were within the range of 80% to 125%.</non_inferiority_desc>
            <param_type>Test / Reference Ratio</param_type>
            <param_value>89.79</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>81.61</ci_lower_limit>
            <ci_upper_limit>98.78</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The Safety Population was defined as all randomized subjects who received at least 1 dose of study drug. The Safety Population included 36 subjects.</time_frame>
      <desc>Adverse events were classified by treatment at onset. Any adverse event that occurred on Day 1 (after check-in) for a given treatment period was assigned to the treatment for that period.</desc>
      <group_list>
        <group group_id="E1">
          <title>10mg MTX</title>
          <description>[Administered via randomized sequence and crossover of Treatment A, Treatment B and Treatment C]</description>
        </group>
        <group group_id="E2">
          <title>15mg MTX</title>
          <description>[Administered via randomized sequence and crossover of Treatment A, Treatment B and Treatment C]</description>
        </group>
        <group group_id="E3">
          <title>20mg MTX</title>
          <description>[Administered via randomized sequence and crossover of Treatment A, Treatment B and Treatment C]</description>
        </group>
        <group group_id="E4">
          <title>25mg MTX</title>
          <description>[Administered via randomized sequence and crossover of Treatment A, Treatment B and Treatment C]</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2.8</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <description>AE Occurred During Treatment B</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <description>AE Occurred During Treatment A</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Maculopapular rash</sub_title>
                <description>AE Occurred During Treatment A</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <description>AE Occurred During Treatment B</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jonathan Jaffe, MD; Vice President Clinical Development</name_or_title>
      <organization>Antares Pharma</organization>
      <phone>1-609-359-3020 ext 324</phone>
      <email>jjaffe@antarespharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

